bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review

bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

bluebird bio Inc (bluebird bio) is a biotechnology company that focuses on the development and commercialization of gene therapies for severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD); betibeglogene autotemcel for transfusion-dependent beta thalassemia; Lovo-cel for the treatment of sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with pharmaceutical companies to discover, develop and commercialize gene therapy products. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

bluebird bio Inc Key Recent Developments

Sep 24,2024: bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
Jul 03,2024: bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
May 29,2024: bluebird bio Appoints O. James Sterling as Chief Financial Officer
Mar 18,2024: bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
bluebird bio Inc - Key Facts
bluebird bio Inc - Key Employees
bluebird bio Inc - Key Employee Biographies
bluebird bio Inc - Major Products and Services
bluebird bio Inc - History
bluebird bio Inc - Company Statement
bluebird bio Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
bluebird bio Inc - Business Description
R&D Overview
bluebird bio Inc - Corporate Strategy
bluebird bio Inc - SWOT Analysis
SWOT Analysis - Overview
bluebird bio Inc - Strengths
bluebird bio Inc - Weaknesses
bluebird bio Inc - Opportunities
bluebird bio Inc - Threats
bluebird bio Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
bluebird bio Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Sep 24, 2024: bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
Jul 03, 2024: bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2024: bluebird bio Appoints O. James Sterling as Chief Financial Officer
Mar 18, 2024: bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
Jan 08, 2024: bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
Dec 13, 2023: ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle Cell Disease (SCD)
Dec 08, 2023: FDA Approves Two Gene Therapies For Sickle Cell Disease
Nov 07, 2023: bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
Oct 30, 2023: bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
Aug 08, 2023: Bluebird Bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
bluebird bio Inc, Key Facts
bluebird bio Inc, Key Employees
bluebird bio Inc, Key Employee Biographies
bluebird bio Inc, Major Products and Services
bluebird bio Inc, History
bluebird bio Inc, Subsidiaries
bluebird bio Inc, Key Competitors
bluebird bio Inc, Ratios based on current share price
bluebird bio Inc, Annual Ratios
bluebird bio Inc, Annual Ratios (Cont...1)
bluebird bio Inc, Annual Ratios (Cont...2)
bluebird bio Inc, Interim Ratios
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
bluebird bio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
bluebird bio Inc, Performance Chart (2019 - 2023)
bluebird bio Inc, Ratio Charts
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings